ERBB2 and breast cancer: TNBC accounts for approximately 15%–20% of all BC cases and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression (Frangou et al., 2014).